298 related articles for article (PubMed ID: 11038071)
21. Low Six4 and Six5 gene dosage improves dystrophic phenotype and prolongs life span of mdx mice.
Yajima H; Kawakami K
Dev Growth Differ; 2016 Aug; 58(6):546-61. PubMed ID: 27224259
[TBL] [Abstract][Full Text] [Related]
22. Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism.
Al-Khalidi R; Panicucci C; Cox P; Chira N; Róg J; Young CNJ; McGeehan RE; Ambati K; Ambati J; Zabłocki K; Gazzerro E; Arkle S; Bruno C; Górecki DC
Acta Neuropathol Commun; 2018 Apr; 6(1):27. PubMed ID: 29642926
[TBL] [Abstract][Full Text] [Related]
23. Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice.
Aoki Y; Nagata T; Yokota T; Nakamura A; Wood MJ; Partridge T; Takeda S
Hum Mol Genet; 2013 Dec; 22(24):4914-28. PubMed ID: 23882132
[TBL] [Abstract][Full Text] [Related]
24. EPA protects against muscle damage in the mdx mouse model of Duchenne muscular dystrophy by promoting a shift from the M1 to M2 macrophage phenotype.
Carvalho SC; Apolinário LM; Matheus SM; Santo Neto H; Marques MJ
J Neuroimmunol; 2013 Nov; 264(1-2):41-7. PubMed ID: 24090650
[TBL] [Abstract][Full Text] [Related]
25. Muscular response to the first three months of deflazacort treatment in boys with Duchenne muscular dystrophy.
Jensen L; Petersson SJ; Illum NO; Laugaard-Jacobsen HC; Thelle T; Jørgensen LH; Schrøder HD
J Musculoskelet Neuronal Interact; 2017 Jun; 17(2):8-18. PubMed ID: 28574407
[TBL] [Abstract][Full Text] [Related]
26. Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy.
Rooney JE; Gurpur PB; Burkin DJ
Proc Natl Acad Sci U S A; 2009 May; 106(19):7991-6. PubMed ID: 19416897
[TBL] [Abstract][Full Text] [Related]
27. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
[TBL] [Abstract][Full Text] [Related]
28. Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy.
Zschüntzsch J; Zhang Y; Klinker F; Makosch G; Klinge L; Malzahn D; Brinkmeier H; Liebetanz D; Schmidt J
J Neurochem; 2016 Jan; 136(2):351-62. PubMed ID: 26230042
[TBL] [Abstract][Full Text] [Related]
29. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
[TBL] [Abstract][Full Text] [Related]
30. Proof-of-concept validation of the mechanism of action of Src tyrosine kinase inhibitors in dystrophic mdx mouse muscle: in vivo and in vitro studies.
Sanarica F; Mantuano P; Conte E; Cozzoli A; Capogrosso RF; Giustino A; Cutrignelli A; Cappellari O; Rolland JF; De Bellis M; Denora N; Camerino GM; De Luca A
Pharmacol Res; 2019 Jul; 145():104260. PubMed ID: 31059789
[TBL] [Abstract][Full Text] [Related]
31. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
[TBL] [Abstract][Full Text] [Related]
32. Cytoplasmic HDAC4 regulates the membrane repair mechanism in Duchenne muscular dystrophy.
Renzini A; Marroncelli N; Cavioli G; Di Francescantonio S; Forcina L; Lambridis A; Di Giorgio E; Valente S; Mai A; Brancolini C; Giampietri C; Magenta A; De Santa F; Adamo S; Coletti D; Moresi V
J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1339-1359. PubMed ID: 35170869
[TBL] [Abstract][Full Text] [Related]
33. Sunitinib promotes myogenic regeneration and mitigates disease progression in the mdx mouse model of Duchenne muscular dystrophy.
Fontelonga TM; Jordan B; Nunes AM; Barraza-Flores P; Bolden N; Wuebbles RD; Griner LM; Hu X; Ferrer M; Marugan J; Southall N; Burkin DJ
Hum Mol Genet; 2019 Jul; 28(13):2120-2132. PubMed ID: 30806670
[TBL] [Abstract][Full Text] [Related]
34. [Muscle regeneration in mdx mouse, and a trial of normal myoblast transfer into regenerating dystrophic muscle].
Takemitsu M; Arahata K; Nonaka I
Rinsho Shinkeigaku; 1990 Oct; 30(10):1066-72. PubMed ID: 2279357
[TBL] [Abstract][Full Text] [Related]
35. Identification of plasma interleukins as biomarkers for deflazacort and omega-3 based Duchenne muscular dystrophy therapy.
de Carvalho SC; Matsumura CY; Santo Neto H; Marques MJ
Cytokine; 2018 Feb; 102():55-61. PubMed ID: 29276972
[TBL] [Abstract][Full Text] [Related]
36. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
Balaban B; Matthews DJ; Clayton GH; Carry T
Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
[TBL] [Abstract][Full Text] [Related]
37. Arginine butyrate: a therapeutic candidate for Duchenne muscular dystrophy.
Vianello S; Yu H; Voisin V; Haddad H; He X; Foutz AS; Sebrié C; Gillet B; Roulot M; Fougerousse F; Perronnet C; Vaillend C; Matecki S; Escolar D; Bossi L; Israël M; de la Porte S
FASEB J; 2013 Jun; 27(6):2256-69. PubMed ID: 23430975
[TBL] [Abstract][Full Text] [Related]
38. Hyperthyroidism impairs early repair in normal but not dystrophic mdx mouse tibialis anterior muscle. An in vivo study.
Pernitsky AN; McIntosh LM; Anderson JE
Biochem Cell Biol; 1996; 74(3):315-24. PubMed ID: 8883837
[TBL] [Abstract][Full Text] [Related]
39. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
[TBL] [Abstract][Full Text] [Related]
40. The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy.
Dorchies OM; Reutenauer-Patte J; Dahmane E; Ismail HM; Petermann O; Patthey- Vuadens O; Comyn SA; Gayi E; Piacenza T; Handa RJ; Décosterd LA; Ruegg UT
Am J Pathol; 2013 Feb; 182(2):485-504. PubMed ID: 23332367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
